Perpignan

Researchers are studying patients with metastatic colorectal cancer (mCRC) who have a specific BRAFV600E mutation. This rare subtype of mCRC has poor prognosis and resistance to current treatments, especially in tumors with microsatellite stability or proficient mismatch repair. The study aims to collect detailed clinical data and biological samples to better understand treatment outcomes, resistance, and survival in real-world settings. Participants will provide blood samples and tumor tissue samples to support various research goals. The study will evaluate circulating tumor DNA during different lines of metastatic treatment to predict treatment response and resistance. It will also analyze the immune environment of BRAFV600E mCRC tumors and study specific subgroups with mismatch repair deficiencies. Clinical management data will be collected to inform future therapeutic approaches. During the study, patients will be monitored regularly with blood sample collections of 30 mL at each time point. Researchers will gather information about treatments, survival, and biological markers over time. The main outcome measured is overall survival from diagnosis up to five years. Patients must be able to comply with study procedures and provide informed consent. The study aims to improve knowledge of this aggressive cancer subtype and support development of new treatments.

Researchers are conducting a French multicenter retrospective study to describe the clinical, histological, and radiological features of rare primary liver cancers. The study aims to collect biological tumor and blood samples and evaluate the effectiveness of treatments used in clinical practice to determine the best therapeutic sequences. This research will serve as the foundation for future translational studies to identify new molecular, histological, circulating, and radiological tumor biomarkers useful for diagnosis, prognosis, and treatment guidance. This study involves collecting data from patients diagnosed with rare liver cancers such as hepatocholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, and hepatic angiosarcoma since January 1, 2018. Both living patients who agree to participate and deceased patients are included. Biological samples and tumor blocks are collected for analysis. Treatments received by patients in routine practice are reviewed to assess their efficacy and help define optimal treatment sequences. Participants provide consent for biological studies if living, and their medical records and tumor characteristics are reviewed. Researchers will describe the clinical, histological, and radiological tumor features and monitor outcomes up to five years from diagnosis. This detailed data collection supports long-term evaluation of rare liver cancers and aids in developing future biomarkers and therapeutic strategies.

Researchers are creating a national, prospective cohort to study children with idiopathic nephrotic syndrome (INS), a rare kidney disease. The goal is to collect detailed data on patients treated in pediatric nephrology centers across France, Reunion Island, Mayotte, and eventually other French overseas territories. This structured follow-up aims to better understand the disease's characteristics and provide a foundation for future clinical trials. The study involves enrolling pediatric patients diagnosed with INS and systematically collecting clinical, biological, psychological, and social data. Biological samples such as blood, urine, hair, and nails will be gathered at disease onset before immunosuppressive treatment begins. Data will be recorded through medical records from hospital visits and consultations, supplemented by annual telephone interviews for patients without active disease. Quality of life, treatment adherence, and aesthetic impact questionnaires will also be collected and integrated into a secure database. Participants will be followed over at least two years, with data collected regularly by clinical research staff. This includes medical validation of clinical information, annual telephone follow-ups, and questionnaire assessments. The study's primary outcome is the number and characteristics of included cases over two years. This ongoing monitoring will support future nested studies and improve understanding of pediatric INS outcomes and management.

Researchers are investigating whether transferring a "blank" culture medium into the uterus a few days before a frozen embryo transfer can improve embryo implantation and pregnancy success in women undergoing in vitro fertilization (IVF). This study focuses on patients who have experienced pregnancy failure after a previous fresh or frozen embryo transfer. The goal is to enhance immune tolerance in the uterus to improve clinical pregnancy rates without increasing multiple pregnancies. The trial compares two procedures: one group receives a "blank" culture medium transfer, where a small amount of embryo culture medium is inserted into the uterine cavity two to three days before the frozen embryo transfer. The other group undergoes a sham transfer using an empty catheter at the same timing. The study is randomized, single-blind, and conducted across multiple centers. Participants' involvement includes undergoing these transfer procedures and subsequent frozen embryo transfers. Researchers will monitor pregnancy outcomes, specifically the clinically progressive pregnancy rate at 12 weeks of amenorrhea. Participants must provide informed consent and be covered by health insurance. The study also monitors for any pregnancy failures following the embryo transfers.

Researchers are studying the management and follow-up of non-muscle-invasive bladder cancer (NMIBC), a type of bladder tumor that affects the inner lining and underlying tissue but not the muscle layer. This cancer type accounts for a significant portion of bladder cancer cases in France, with many patients experiencing tumor recurrence within five years. The study aims to evaluate the diagnostic accuracy of urine biomarker tests compared to bladder endoscopy, which is the current standard for detecting tumor recurrence. Additionally, it will describe tumor characteristics, patient history, treatments, and regional differences in care. Patients being monitored for NMIBC and undergoing routine care will have their medical details, including prior treatments and urine test results, recorded in a registry. Follow-up includes regular bladder endoscopy exams, with dates and findings noted by urologists. Urine test results taken before biopsies will also be tracked. This observational study will analyze the performance of urine tests by calculating sensitivity, specificity, and predictive values, and exploring differences based on tumor grade, stage, and previous treatments. The goal is to include 8000 patients across France over six years. Participants will provide data through medical records and routine exams during their personalized care plans. Urine samples and bladder fibroscopy results will be collected at each follow-up visit to assess test accuracy over a five-year period. Researchers will monitor recurrence-free survival and urine test performance, aiming to identify if urine tests can safely reduce the need for invasive cystoscopy. The study focuses on long-term monitoring to better understand and improve care for NMIBC patients.

Researchers are evaluating the effectiveness of different antimicrobial treatments for infections caused by difficult-to-treat Pseudomonas aeruginosa bacteria. This infection is especially challenging for patients who are critically ill or have weakened immune systems. The study focuses on comparing new beta-lactam/beta-lactamase inhibitor combinations, cefiderocol, and older drugs like aminoglycosides and colistin in real-life clinical settings across multiple hospital centers in France. Participants will receive intravenous antimicrobial therapy tailored to treat their difficult-to-treat P. aeruginosa infection. The study observes the use of new and older antimicrobial drugs to assess their clinical efficacy. Patient data and bacterial samples will be collected and analyzed centrally to better understand drug resistance mechanisms and treatment outcomes. Participants will be monitored for clinical cure shortly after completing therapy and on Day 7 ± 2 days. Researchers will collect clinical information through electronic case-report forms and send bacterial isolates to a national center for detailed testing. Outcomes include cure rates, resistance development, adverse events, and mortality rates, with follow-up during hospitalization and up to 28 days after treatment. The study aims to provide valuable real-world data on treating these challenging infections.

This research is focused on patients diagnosed with Atypical Hemolytic-Uremic Syndrome (aHUS). It aims to gather post-marketing safety data for patients treated with the drugs eculizumab or ravulizumab, as well as to monitor the progression of the disease in all participating patients regardless of treatment status. The study is observational and non-interventional, conducted across multiple centers and countries. No specific treatments or interventions are administered as part of this study; rather, it observes patients who have already been treated or untreated with eculizumab or ravulizumab. The study collects data from these patients over time to understand safety outcomes and disease progression. Participants will be followed to record the proportion experiencing certain events over a period of 10 years and the timing of first and subsequent occurrences of these events over 5 years. The study involves gathering clinical information and safety data through routine monitoring. Patients or their guardians provide informed consent and may be asked for assent if applicable. The study tracks long-term outcomes and safety in aHUS patients.

Researchers are studying Philadelphia-negative myeloproliferative neoplasms (MPN), which include Polycythemia Vera (PV), essential thrombocythemia (ET), and prefibrotic myelofibrosis (PreMF). These chronic blood cancers involve specific mutations like JAK2V617F and carry a high risk of blood clots that can cause serious health problems. Current treatments include low-dose aspirin to reduce arterial clots, but patients still face risks of thrombosis and bleeding. This trial explores whether direct oral anticoagulants (DOACs), such as Apixaban or Rivaroxaban, might better prevent these clotting events in patients with the JAK2V617F mutation. Participants will be randomly assigned to receive either a DOAC (Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once daily) or low-dose aspirin (100 mg once daily). The study focuses on high-risk MPN patients with JAK2V617F mutation and will compare the effectiveness and safety of DOACs versus aspirin for preventing blood clots. Treatment will continue with close monitoring throughout the study. During the study, researchers will track the time until any arterial or venous blood clots occur over a 24-month follow-up period. Participants will undergo regular assessments to monitor clotting events, bleeding risks, and overall health. The trial aims to gather detailed information on how well these treatments prevent thrombosis and their safety profiles, helping to guide future care for patients with these blood disorders.

Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease that affects only women who have breast implants. Due to the rarity and unique type of this disease, French authorities have recommended creating a registry to track BIA-ALCL cases. This registry operates in France and Belgium in connection with a national multidisciplinary meeting for case review. This study involves an observational registry that does not include any treatment or intervention. It collects and records data from adult women diagnosed with BIA-ALCL to better understand the disease and its characteristics. Participants in this registry provide information about their diagnosis and disease course. Researchers monitor overall response to the disease over a period of 13 years. The registry helps experts gather important data to support future research and improve understanding of BIA-ALCL in affected women.

Researchers are comparing the visual outcomes of two types of intraocular lenses (IOLs), the Synthesis Plus and the Synthesis Plus Toric, in adults undergoing cataract surgery. The study aims to determine whether the Synthesis Plus Toric lens is not inferior to the Synthesis Plus lens in terms of distance-corrected intermediate visual acuity at 66 cm, measured one month after implantation. This study involves patients over 50 years old who require bilateral cataract surgery and have specific levels of corneal astigmatism. Participants will receive implantation of either the Synthesis Plus IOL or the Synthesis Plus Toric IOL, depending on their corneal astigmatism. The Synthesis Plus Toric lens is designed for patients with pre-existing astigmatism, while the Synthesis Plus lens is for those with minimal or no astigmatism. Both devices are implanted during cataract surgery, and the expected postoperative astigmatism must be within defined limits. The study monitors patients for visual acuity outcomes one month after lens implantation. During the study, participants will undergo visual acuity assessments, including distance-corrected intermediate visual acuity at 66 cm. Researchers will evaluate these outcomes to compare the lenses' performance. Participants must be willing and able to comply with examination procedures and provide informed consent. Safety and effectiveness are evaluated through monitoring postoperative visual acuity and any complications related to surgery or lens placement.